AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Inspire Medical Systems reduces FY23 revenue outlook, blames slow commercial launch.
ByAinvest
Tuesday, Sep 2, 2025 10:06 am ET1min read
• Inspire Medical Systems reports Q2 financial results • Revenue outlook reduced to $900-$910 million • Diluted net income per share reduced to $0.40-$0.50 • Slower-than-expected commercial launch of next generation Inspire model • Pomerantz LLP investigating potential securities fraud • Investors advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980
Inspire Medical Systems (NYSE: INSP), a leading provider of sleep apnea treatment implants, has reaffirmed its updated 2025 financial guidance following its Q2 results. The company significantly reduced its full-year revenue outlook to $900 million - $910 million and diluted net income per share to $0.40 - $0.50, citing slower-than-expected uptake of its next-generation device, the Inspire V [1].The company's stock price fell $42.04 per share, or 32.35%, to close at $87.91 on August 5, 2025, following the announcement [1]. Inspire Medical Systems also announced that its Chief Financial Officer, Rick Buchholz, will step down at the end of 2025 and transition to a financial advisory role until February 2026 [3].
Pomerantz LLP, a prominent securities litigation firm, has initiated an investigation into potential claims on behalf of investors of Inspire Medical Systems. The investigation focuses on whether the company and its officers and/or directors have engaged in securities fraud or other unlawful business practices [2]. Investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980, for more information about the investigation [2].
Inspire Medical Systems' reaffirmation of its full-year 2025 financial guidance signals operational confidence during a period of executive transition. The maintained guidance suggests that the company sees current executive transitions as manageable in the context of ongoing business objectives [3].
References:
[1] https://seekingalpha.com/news/4489337-inspire-medical-reaffirms-updated-2025-guidance
[2] https://www.ainvest.com/news/inspire-medical-systems-reduces-fy23-revenue-outlook-900mln-910mln-2508/
[3] https://finance.yahoo.com/news/did-cfo-transition-reaffirmed-outlook-101442119.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet